BUSINESS COMBINATION (Details) - USD ($)		3 Months Ended				9 Months Ended
	Mar. 10, 2022	Dec. 31, 2023	Sep. 30, 2023	Dec. 31, 2022	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022	Aug. 03, 2022	Jul. 29, 2022
BUSINESS COMBINATION
Common stock, shares issued			17,762,998	15,844,294		17,762,998			2,459,016
Common stock, price per share			$ 0.001	$ 0.001		$ 0.001		$ 0.001
Fair value adjustment decrease to contingent consideration						$ (999,000)	$ (244,000)
V C N
BUSINESS COMBINATION
Common stock, shares issued	2,639,530
Common stock, price per share	$ 0.001
Amount to be paid due to approval				$ 3,000,000.0
Finance costs	$ 417,000
Fair value of contingent consideration	11,093,000		$ 5,900,000	10,200,000		5,900,000
Operating expense of fair value increase to contingent consideration			1,600,000			$ 1,000,000.0
Fair value adjustment decrease to contingent consideration					$ 227,000		$ 244,000
Purchase consideration	22,809,000		$ 3,250,000
V C N | General and administrative expenses
BUSINESS COMBINATION
Fair value of contingent consideration	27,800,000
V C N | Grifols Innovation
BUSINESS COMBINATION
Consideration purchase paid	4,700,000
Existing liabilities	2,390,000
Cash payments	$ 70,200,000
Amount to be paid due to approval				$ 3,000,000.0
Amount paid for initiated patient dosing		$ 3,250,000
V C N | New technologies
BUSINESS COMBINATION
Business acquisition, percentage of voting interests acquired	86.00%